secwatch / observer
8-K filed January 23, 2024, 6:59 PM ET CIK 0001504167
M&A confidence high sentiment negative materiality 1.00

TREX WIND-DOWN, INC.: M&A transaction — Timber Pharmaceuticals completes asset sale to LEO Pharma for $14.35M in Chapter 11

TREX WIND-DOWN, INC.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John Koconis

Chief Executive Officer, President and Chairman of the Board
TREX WIND-DOWN, INC.
Effective
2024-01-22
Filed
January 23, 2024, 6:59 PM ET
Effective as of the closing of the Asset Sale, each of John Koconis, Chief Executive Officer, President and Chairman of the Board, and Joseph Lucchese, Chief Financial Officer, Treasurer and Secretary, resigned from their respective executive officer and other employment positions they held with the Company and the Company’s subsidiaries, as applicable, and assumed employment positions with LEO Spiny Merger Sub, Inc.
Departed

Joseph Lucchese

Chief Financial Officer, Treasurer and Secretary
TREX WIND-DOWN, INC.
Effective
2024-01-22
Filed
January 23, 2024, 6:59 PM ET
Effective as of the closing of the Asset Sale, each of John Koconis, Chief Executive Officer, President and Chairman of the Board, and Joseph Lucchese, Chief Financial Officer, Treasurer and Secretary, resigned from their respective executive officer and other employment positions they held with the Company and the Company’s subsidiaries, as applicable, and assumed employment positions with LEO Spiny Merger Sub, Inc.
Departed

Alan Mendelsohn

Chief Medical Officer
TREX WIND-DOWN, INC.
Effective
2024-01-22
Filed
January 23, 2024, 6:59 PM ET
Also effective as of the closing of the Asset Sale, Alan Mendelsohn, Chief Medical Officer, no longer serves as Chief Medical Officer of the Company and any other positions with the Company’s subsidiaries, as applicable and has been offered employment with LEO Spiny Merger Sub, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Koconis resigned as Chief Executive Officer, President and Chairman of the Board at TREX WIND-DOWN, INC..

Action
resigned
Role
Chief Executive Officer, President and Chairman of the Board
Exact text from the filing
Effective as of the closing of the Asset Sale, each of John Koconis, Chief Executive Officer, President and Chairman of the Board, and Joseph Lucchese, Chief Financial Officer, Treasurer and Secretary, resigned from their respective executive officer and other employment positions they held with the Company and the Company’s subsidiaries, as applicable, and assumed employment positions with LEO Spiny Merger Sub, Inc.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Lucchese resigned as Chief Financial Officer, Treasurer and Secretary at TREX WIND-DOWN, INC..

Action
resigned
Role
Chief Financial Officer, Treasurer and Secretary
Exact text from the filing
Effective as of the closing of the Asset Sale, each of John Koconis, Chief Executive Officer, President and Chairman of the Board, and Joseph Lucchese, Chief Financial Officer, Treasurer and Secretary, resigned from their respective executive officer and other employment positions they held with the Company and the Company’s subsidiaries, as applicable, and assumed employment positions with LEO Spiny Merger Sub, Inc.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Alan Mendelsohn departed as Chief Medical Officer at TREX WIND-DOWN, INC..

Action
no longer serves
Role
Chief Medical Officer
Exact text from the filing
Also effective as of the closing of the Asset Sale, Alan Mendelsohn, Chief Medical Officer, no longer serves as Chief Medical Officer of the Company and any other positions with the Company’s subsidiaries, as applicable and has been offered employment with LEO Spiny Merger Sub, Inc.
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

TREX WIND-DOWN, INC. completed a disposition involving LEO Pharma A/S for $14.35 million (closed 2024-01-22).

Action
disposition
Counterparty
LEO Pharma A/S
Consideration
$14.35 million
Closing
2024-01-22
Exact text from the filing
Agreement. the Debtors agreed to sell substantially all of the assets of the Company and its subsidiaries, including TMB-001, to LEO (the “Asset Sale”), for a purchase price of $14.35 million (the “Purchase Price”) plus the assumption of certain liabilities, subject to approval by the Bankruptcy Court and other agreed-upon conditions. On January 22, 2024, the
View on SEC.gov

21 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Source: SEC EDGAR
accession 0001493152-24-003336
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.